KANE BIOTECH

TSX-V:KNE OTC:KNBIF

Market Cap
C$8.01M

Shares Outstanding
80.1M

Debt
$0

Corporate Milestones

2018

- ☑ Uplist to OTCQB Venture Market
- ☑ Retain Investor Relations Counsel
- ☑ File lawsuit against Nestlé to defend Kane Biotech intellectual property
- ❑ Existing license expansion
  - Geography
  - Product applications
- ❑ Achieve International standard of efficacy
- ❑ Launch DispersinB® based products
- ❑ Execute new license agreements
- ❑ Initiate clinical trials for technologies treating human chronic inflammatory skin disorders

Key Highlights

- Specialized focus on large markets for biofilm prevention and dispersion solutions
- Strong patent portfolio of anti-biofilm technologies with 75 patents and patents pending
- First commercial licensing & distribution agreement signed (2017)
- Several anti-biofilm applications in development for large market opportunities

Corporate Overview

Kane Biotech is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane Biotech's mission is to be a royalty based revenue company licensing its anti-biofilm technologies to global industry players.

Companion Pet Market

Kane Biotech's premium companion pet oral care products, StrixNB™ and bluestem™, are targeted at multiple channels, including veterinary clinics, pet specialty retail, grocery/mass merchants, and e-commerce. DispersinB® is a powerful biofilm dispersion enzyme. Initial targeted applications include otic ear infections and skin infections. Kane's StrixNB™ & DispersinB® technologies are licensed to Dechra Pharmaceuticals (LON:DPH) for distribution in the North American veterinary channel. Dechra markets the StrixNB™ technology under its Vetradent™ brand name.

Human and Industrial Applications

Kane Biotech has several formulations in development based on its proprietary anti-biofilm technologies that have the potential to treat human health skin disorder conditions such as athlete's foot, eczema, & seborrheic dermatitis. The company's antimicrobial and anti-biofilm technologies also have applications in hospitals, medical device decontamination, food production & safety, and industrial process control environments.

Corporate & Commercial Strategy

Discovery
- Internal R & D discovery engine
- Academic collaborations: Rutgers University - USA, University of Toronto & University of Manitoba - Canada

Development
- Development and testing of prototypes
- Pre-clinical performance, efficacy, safety & stability tests
- Joint development agreements

Commercialization
- In-house GMP product manufacturing capabilities
- Test products for market acceptance
- Partnerships or licensing and distribution agreements

Four Step Approach to Commercialization

1. **Canada as a Test Market for Companion Pet Oral Care**
   - ✓ Products based on science, safety, efficacy & value
   - ✓ Branding, premium packaging & positioning, marketing plan development, advertising, veterinary endorsements
2. **Conclude Market Access Partner**
   - ✓ 10+ year royalty agreement signed with major player
3. **Geographic Expansion with Partner**
   - Europe, Asia, ROW
   - Discussions in progress
4. **Conclude Additional Partner(s) for Pet Specialty, Grocery / Mass & e-commerce**
   - Discussions in progress

Market Opportunities

Companion Pet – Oral Care & Skin Care

$69 billion
US Pet Product Market has tripled since 1996

$105 billion
Global Pet Products Market

80 million
Homes in the US have a companion pet

$1.5 billion
Spent worldwide on pet oral care alone

Human Dermatology

Athlete's Foot
- Afflicts 15% of world population
- $881M global market

Atopic Dermatitis (Eczema)
- Afflicts 10% of adults and 25% of children globally
- $5.6B global market by 2022

Seborrheic Dermatitis (& Chronic Dandruff)
- Fastest growing hair care segment
- $6B global market by 2020

Understanding Biofilms



- Biofilms are thin, slimy films of bacteria that attach to and grow on living and inert surfaces. More simply they are the fortresses that bacteria build to protect themselves
- Bacteria in biofilms can be up to 1000x more resistant to antibiotics, biocides, and disinfectants than planktonic free-floating bacteria
- Biofilms are estimated to be involved in 80% of animal and human bacterial infections, including tooth decay, skin disorders, hospital acquired infections (HAIs), chronic wounds, and foodborne disease outbreaks

Cost of Antibiotic Resistance

Hospital Acquired Infections (HAIs)

- HAIs cost the US over $9B annually[1]
- One "superbug", MRSA, kills more Americans each year than HIV/AIDS, Parkinson's disease, emphysema, and homicide combined[2]
- Authorities estimate that 700k people die annually worldwide due to antibiotic resistance
- By 2050, an estimated 10 million people will die annually due to antimicrobial resistance (AMR) unless a global response to AMR is mounted

Foodborne Illnesses

- Foodborne outbreaks cause approximately 76 million illnesses, 325,000 hospitalizations, and 5,000 deaths in the United States each year
- Foodborne illnesses cost the US more than $15.6B annually[3]
- The average cost of a recall to a food company is $10 million in direct costs, in addition to brand damage and lost sales

1: https://cddep.org/tool/overall_and_unit_costs_five_most_common_hospital_acquired_infections_hais_us/
2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/
3: http://www.foodsafetynews.com/2014/10/foodborne-illnesses-cost-usa-15-6-billion-annually/#.WniKIKinGUI

> *"Antimicrobial resistance is now one of our most serious health threats. Infections from resistant bacteria are now too common and some pathogens have even become resistant to multiple types or classes of antibiotics."*
>
> - Tom Frieden, Director of the Center for Disease Control and Prevention, *Meeting the Challenges of Drug Resistant Diseases in Developing Countries*

> *"The world is facing an antibiotic apocalypse. Unless action is taken to halt the practices that have allowed antimicrobial resistance to spread and ways are found to develop new types of antibiotics, we could return to the days when routine operations, simple wounds or straightforward infections could pose real threats to life."*
>
> - Sally Davies, England's chief medical officer

Pet Oral Care Health Products

STRIX NB™
A SMARTER WAY TO FIGHT BACTERIA

- ✓ Product designed based on science, safety and efficacy
- ✓ Multiple mediums for oral care, including toothpaste, water additive, oral spray, dental chews, wipes and rawhides
- ✓ Licensed to Dechra Veterinary Products for North American veterinary channel
- ✓ Notified under Health Canada's VHP (Veterinary Health Products) program

bluestem oral care

- ✓ Sold in 895 pet specialty stores in Canada/US
- ✓ Efficacy study results showed statistically significant reduction in tartar, safety studies conducted at 5x recommended dose
- ✓ Water additive and oral spray are convenient and easy to use
- ✓ Notified under Health Canada's VHP (Veterinary Health Products) program

Dechra
Veterinary Products

Agreement – Mar. 2017

- **10+ yr exclusive License & Distribution agreement**
- **N.American vet market only**
- **Incorporates StrixNB™ and DispersinB®**
- **$500,000 USD on signing**
- **Commercial milestones to max of $2M USD + ongoing royalties, subject to minimums**

Management

Mark Ahrens-Townsend, *President & CEO*
Ray Dupuis, *Chief Financial Officer*
Grant Humphrey, *VP Sales*
Nanda Yakandawala, *Senior Research Scientist*
Wendy Nachtigall, *Director of Marketing*

Board of Directors

Mark Ahrens-Townsend, *President & CEO*
Philip Renaud, *Chairman*
Mark Nawacki, *Director*
Marc Edwards, *Director*
Dr. Sarah Prichard, *Advisor*

Investor Relations

Tirth Patel
Investor Relations, Edison Advisors
tpatel@edisongroup.com